Want to see HK:1093 full AI Analyst Report?
CSPC Pharmaceutical Group (1093) AI Stock Analysis
CSPC Pharmaceutical Group
(HKEX:1093)
The score is driven primarily by strong financial quality—especially the very low leverage balance sheet and resilient profitability—supported by reasonable valuation (P/E ~12.56 and ~3.05% yield). Technicals are constructive with the price above key moving averages and neutral-to-positive momentum, though the overall score is moderated by recent revenue softness and margin compression versus earlier years.
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 12.66B
- Dividend Yield
- 4.20%
- Average Volume (3M)
- 86.89M
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 0.66
- Revenue Growth
- 25.21%
- EPS Growth
- 103.93%
- Country
- Hong Kong
- Employees
- 18,626
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
CSPC Pharmaceutical Group Business Overview & Revenue Model
Company Description
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of C...
How the Company Makes Money
CSPC Pharmaceutical Group makes money primarily by selling pharmaceutical products and related services through its operating subsidiaries. Its core revenue model is product-based: (1) Sales of finished pharmaceutical products: The company generates...
CSPC Pharmaceutical Group Financial Statement Overview
Summary
Overall fundamentals are strong, led by an exceptionally conservative balance sheet (very low leverage) and still-healthy profitability. Offsetting factors include softer recent growth (revenue declines in 2023–2024, low-single-digit growth in 2025) and margin compression versus prior peaks, though 2025 free cash flow rebounded meaningfully.
Income Statement
74PositiveBalance Sheet
92Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.86B | 25.33B | 29.54B | 31.47B | 31.59B | 27.41B |
| Gross Profit | 22.17B | 16.62B | 20.67B | 22.19B | 22.73B | 20.79B |
| EBITDA | 9.99B | 5.24B | 7.16B | 8.59B | 8.83B | 7.58B |
| Net Income | 7.32B | 3.78B | 4.41B | 5.88B | 6.22B | 5.51B |
Balance Sheet | ||||||
| Total Assets | 56.01B | 46.72B | 44.36B | 46.28B | 41.18B | 34.68B |
| Cash, Cash Equivalents and Short-Term Investments | 18.48B | 8.87B | 7.75B | 13.09B | 13.87B | 10.73B |
| Total Debt | 652.37M | 641.38M | 507.33M | 706.90M | 582.54M | 93.87M |
| Total Liabilities | 16.59B | 12.15B | 10.52B | 11.26B | 10.06B | 7.91B |
| Stockholders Equity | 37.62B | 33.19B | 32.24B | 33.20B | 29.77B | 25.94B |
Cash Flow | ||||||
| Free Cash Flow | 12.21B | 3.99B | 1.74B | 2.29B | 6.62B | 2.88B |
| Operating Cash Flow | 13.78B | 5.90B | 4.26B | 4.18B | 8.10B | 4.64B |
| Investing Cash Flow | -8.65B | -4.13B | -4.41B | 607.27M | -7.19B | -637.33M |
| Financing Cash Flow | -2.21B | -2.44B | -5.11B | -2.30B | -1.95B | -2.20B |
CSPC Pharmaceutical Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1093, the sentiment is Negative. The current price of 7.87 is below the 20-day moving average (MA) of 8.74, below the 50-day MA of 8.98, and below the 200-day MA of 8.49, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.77 is Neutral, neither overbought nor oversold. The STOCH value of 10.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1093.
CSPC Pharmaceutical Group Peers Comparison
Overall Rating
- HK:109380Outperform
HK:332068Neutral
HK:086761Neutral
HK:117761Neutral
HK:260758Neutral
HK:087457Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1093 | 80Outperform | HKD 90.26B | 10.27 | 20.68% | 4.20% | 25.21% | 103.93% |
| HK:3320 | 68Neutral | HKD 29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% |
| HK:0867 | 61Neutral | HKD 23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% |
| HK:1177 | 61Neutral | HKD 85.83B | 30.75 | 7.56% | 2.49% | 14.57% | -31.09% |
| HK:2607 | 58Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| HK:0874 | 57Neutral | HKD 35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1093 | CSPC Pharmaceutical Group | 7.87 | 0.50 | 6.75% | |
| HK:1177 | Sino Biopharmaceutical | 4.82 | -2.13 | -30.64% | |
| HK:0867 | China Medical System Holdings | 9.81 | -3.65 | -27.10% | |
| HK:0874 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H | 12.86 | -5.10 | -28.41% | |
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:3320 | China Resources Pharmaceutical Group Ltd. | 4.63 | -0.11 | -2.26% |
CSPC Pharmaceutical Group Corporate Events
CSPC launches Phase I/II trial for new B7‑H3 ADC in China
CSPC Pharmaceutical Group Limited, a Hong Kong–incorporated biopharmaceutical company, develops and markets innovative drugs, with a particular focus on oncology and other high‑value therapeutic areas. The group is building a pipeline of...
CSPC Launches Phase I Trial of mRNA Cancer Vaccine SYS6077 in China
CSPC Pharmaceutical Group has initiated a Phase I multi-centre clinical trial in China for SYS6077, an injectable Class 1 therapeutic biological product designed as a universal off-the-shelf mRNA cancer vaccine for advanced malignant tumours. The com...
CSPC Innovation Posts Strong Nine-Month Revenue and Profit Surge
CSPC Pharmaceutical Group announced that its subsidiary CSPC Innovation Pharmaceutical has released unaudited financial results for the nine months ended 30 September 2026, as required by the Shenzhen Stock Exchange. The report shows operating revenu...
CSPC’s Novel Immuno-Oncology Drug Shows Early Promise in Advanced Solid Tumours
CSPC Pharmaceutical Group reported positive first-in-human Phase I/II data for SYS6090 (JMT108), an anti-PD-1/IL-15 bifunctional fusion protein, in patients with advanced solid tumours who had failed standard therapies. The results were highlighted i...
CSPC’s B7-H3 ADC Shows Strong Phase I/II Results in Advanced Breast Cancer
CSPC Pharmaceutical Group has independently developed SYS6043, a B7-H3-targeted antibody-drug conjugate, as part of its expanding oncology pipeline focused on advanced solid tumours. The company is positioning itself as a key regional innovator in ca...
CSPC’s Anbenitamab Delivers Major Survival Gain in HER2-Positive Gastric Cancer Trial
CSPC Pharmaceutical Group reported updated overall survival results from its Phase III KC-WISE trial of Anbenitamab Injection (Ennituo) plus chemotherapy in HER2-positive advanced gastric and gastro-oesophageal junction adenocarcinoma patients who ha...
CSPC’s Anbenitamab Combo Delivers Superior Results in HER2-Positive Breast Cancer Trial
CSPC Pharmaceutical Group announced interim Phase III results from the HEALER study, showing its Anbenitamab injection, branded Ennituo, combined with albumin-bound docetaxel, significantly outperformed the long-standing THP regimen in first-line tre...
CSPC Wins China Approval for First-in-Class Batoclimab Therapy in Myasthenia Gravis
CSPC Pharmaceutical Group announced that its in-licensed Batoclimab subcutaneous injection, marketed as Enlida, has received a drug registration certificate from China’s National Medical Products Administration for use with conventional therapi...
CSPC Starts Phase II Trial of New RSV Drug SYH2066 in China
CSPC Pharmaceutical Group has officially begun a Phase II clinical trial in China for SYH2066, an orally administered small-molecule inhibitor targeting the fusion protein of respiratory syncytial virus. The candidate, classified as a Class 1 chemica...
CSPC Launches Phase III Trial for Novel Triple-Negative Breast Cancer Drug in China
CSPC Pharmaceutical Group has initiated a Phase III clinical trial in China for SYS6043, a B7-H3-targeted antibody-drug conjugate designed as a first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer....
CSPC Launches Phase I Trial of Dual-Target Dry Eye Drug SYH2083 in China
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2083, an investigational eye drop developed to treat dry eye disease through a dual-target mechanism. The company is conducting the trial in healthy participants to asse...
CSPC Pharma Grants 78 Million Restricted Shares Under 2026 Incentive Scheme
CSPC Pharmaceutical Group has granted 78,085,000 restricted shares, equal to about 0.678% of its issued share capital, to 205 employees under its 2026 Restricted Share Award Scheme. The shares, priced at HK$2.95 versus a market closing price of HK$8....
CSPC Wins China Trial Nod for Innovative Trispecific Cancer Antibody
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6088 Injection, a recombinant humanised trispecific antibody targeting PD-1, VEGFA and CTLA-4 in advanced or me...
CSPC Grants 33.98 Million Restricted Shares Under Long-Term Incentive Plan
CSPC Pharmaceutical Group has granted 33,980,000 restricted shares, equal to about 0.29% of its issued share capital, to 260 employees under its 2018 Share Award Scheme at no purchase price. The shares will vest in five tranches between January 2027...
CSPC Wins China Trial Nod for New Cancer Antibody-Drug Conjugate
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6062, a monoclonal antibody-drug conjugate targeting advanced solid tumours. The preclinical data showed anti-t...
CSPC Advances Nectin-4 ADC SYS6002 in Cervical Cancer After Positive Phase I Data
CSPC Pharmaceutical Group has reported Phase I data for SYS6002, a next-generation Nectin-4–targeting antibody-drug conjugate, used as a monotherapy in advanced cervical cancer and presented the results at the 2026 Annual Global Meeting of the...
CSPC to Showcase Breakthrough HER2 Oncology Data at ESMO 2026
CSPC Pharmaceutical Group will present data from eight oncology clinical trials at the ESMO Congress 2026 in Madrid, including two late-breaking abstracts spanning breast, lung, gastric, liver, colorectal, pancreatic cancers and rare tumours. The mix...
CSPC’s Efmedaglutide Shows Strong Phase III Results Against Dulaglutide in Chinese Diabetes Trial
CSPC Pharmaceutical Group has reported positive Phase III trial results for its GLP-1 receptor agonist Efmedaglutide Alfa (TG103 Injection), used once weekly in combination with metformin in Chinese adults with type 2 diabetes mellitus. Presented at...
CSPC Wins U.S. FDA Nod for Clinical Trials of Recombinant Shingles Vaccine
CSPC Pharmaceutical Group has received U.S. Food and Drug Administration approval to begin clinical trials for its recombinant herpes zoster vaccine SYS6052, following earlier trial clearance in China. The vaccine targets adults aged 50 and above and...
CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China
CSPC Pharmaceutical Group has initiated a Phase Ib clinical trial in China for JMT206, a recombinant fully human monoclonal antibody designed for weight management in adults with overweight or obesity. The drug targets activin receptor type IIA and I...
CSPC Wins China Trial Nod for Novel mRNA Cancer Vaccine SYS6077
CSPC Pharmaceutical Group has received Chinese regulatory approval to begin clinical trials of SYS6077, an off‑the‑shelf therapeutic mRNA cancer vaccine designed for patients with advanced malignant tumours. The candidate uses the company...
CSPC’s Becotatug Combo Hits Key Goal in Phase III EGFR ex20ins Lung Cancer Trial
CSPC Pharmaceutical Group reported that its Phase III trial of Becotatug (JMT101) combined with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations achieved its prima...
CSPC Launches Phase III Trial of Albumin-Bound Docetaxel for Advanced Breast Cancer in China
CSPC Pharmaceutical Group has officially initiated a Phase III clinical trial in China for HB1801, an albumin-bound docetaxel injection developed via its nanomedicine platform for treating advanced breast cancer. The company positions HB1801 as a nex...
CSPC Advances Novel Dual-Target Diabetes Drug Into Phase II Trial in China
CSPC Pharmaceutical Group has officially launched a Phase II multicentre clinical trial in China for SYH2069 Injection, a novel long-acting dual GLP-1 and GIP receptor agonist for adult patients with type 2 diabetes mellitus. The therapy is engineere...
CSPC’s ADC SYS6010 Wins Breakthrough Status in China for Hard-to-Treat Lung Cancer
CSPC Pharmaceutical Group announced that its antibody-drug conjugate SYS6010 has received Breakthrough Therapy Designation from China’s National Medical Products Administration for recurrent or metastatic actionable genomic alteration-negative...
CSPC Advances SYS6010 Lung Cancer Combo After Strong Phase I/II Data
CSPC Pharmaceutical Group reported Phase I/II trial data for SYS6010, an EGFR-targeting antibody-drug conjugate, combined with PD-1 inhibitor Enlonstobart in treatment-naive, advanced non-small cell lung cancer patients lacking actionable genomic alt...
CSPC Wins China Trial Nod for First Ready-to-Use Goserelin Injection
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its goserelin sustained-release injection, SYH9102, the world’s first ready-to-use formulation of this GnRH...
CSPC Wins NMPA Nod for First Subcutaneous Long-Acting Rotigotine Parkinson’s Trial in China
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its rotigotine long-acting injection SYH9087 for Parkinson’s disease. The once-weekly subcutaneous formulati...
CSPC Wins China Trial Approval for Innovative SYH2083 Eye Drops
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for SYH2083 eye drops, a Class 1 innovative small-molecule ophthalmic drug for dry eye disease. The therapy, which re...
CSPC Launches Phase II Trial of Novel Influenza Drug in China
CSPC Pharmaceutical Group Limited, a Hong Kong-based pharmaceutical developer, is expanding its pipeline of innovative small-molecule drugs tailored to significant disease burdens in China. The company is increasingly focused on advancing Class 1 che...
CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications
CSPC Pharmaceutical Group announced that its EGFR-targeting antibody-drug conjugate SYS6010 has received another Breakthrough Therapy Designation from China’s National Medical Products Administration for treating recurrent or metastatic head an...
CSPC Launches Phase I Trial of Novel Depression Drug SYH2056 in China
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2056, an investigational small-molecule 5-HT2A partial agonist tablet intended for the treatment of depression. The study will assess safety, tolerability, pharmacokinet...
CSPC Launches First China Trial for New Obesity Drug SYH2092
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2092, an injectable amylin receptor agonist developed for weight management in adults with overweight or obesity. The trial, launched after regulatory approval in August...
CSPC Advances Dual-Agonist Obesity Drug SYH2069 Into Phase II Trial in China
CSPC Pharmaceutical Group has initiated a Phase II clinical trial in China for SYH2069 Injection, a novel long-acting dual agonist targeting GLP-1 and GIP receptors for weight management in overweight and obese adults. The drug is designed to enhance...
CSPC Wins China Trial Approval for Novel Obesity and Diabetes Drug
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its SYH2092 injection, a highly potent amylin receptor agonist designed for weight management and glycaemic contro...
CSPC Cancer Drug SYS6090 Wins U.S. FDA Fast Track Status
CSPC Pharmaceutical Group announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration for treating microsatellite-stable or proficient mism...
CSPC’s EGFR-Targeting ADC Hits Phase III Milestone in Resistant Lung Cancer
CSPC Pharmaceutical Group reported that its investigational drug SYS6010, an EGFR-targeting antibody-drug conjugate, met the pre-specified primary endpoint of progression-free survival in a Phase III trial for EGFR-mutated locally advanced or metasta...
CSPC Wins U.S. and China Approvals to Trial New RSV Vaccine in Seniors
CSPC Pharmaceutical Group has received approval from the U.S. Food and Drug Administration and China’s National Medical Products Administration to begin clinical trials for its recombinant respiratory syncytial virus vaccine SYS6057 in adults a...
CSPC Pharmaceutical Profit More Than Doubles on Finished Drug Growth
CSPC Pharmaceutical Group reported strong interim results for the six months ended 30 June 2026, driven mainly by robust growth in its finished drugs segment. Group revenue rose 40.1% year-on-year to RMB18.59 billion, while reported profit attributab...
CSPC Pharmaceutical Declares Interim Dividend for First Half of 2026
CSPC Pharmaceutical Group Limited has declared an interim ordinary cash dividend of HKD 0.18 per share for the six months ended 30 June 2026, payable in Hong Kong dollars. The ex-dividend date is set for 20 October 2026, with the record date on 26 Oc...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Drug for Liver Cancer in China
CSPC Pharmaceutical Group has officially initiated a Phase Ib/II clinical trial of SYS6090 Injection, a Class 1 therapeutic biological product, at the first centre in China for the treatment of hepatocellular carcinoma. SYS6090 is a recombinant fully...
CSPC Seeks Priority Approval in China for Novel HER2-Positive Breast Cancer Regimen
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under a priority review procedure, a new drug application for the combination of Anbenitamab (KN026) and its albumin-bound docetaxel (HB1801...
CSPC Innovation Posts Strong Interim Turnaround With Tripled Revenue and Robust Profit
CSPC Pharmaceutical Group’s Shenzhen‑listed subsidiary, CSPC Innovation Pharmaceutical, released unaudited interim results for the six months ended 30 June 2026 showing a sharp turnaround to profitability. Revenue surged 208.72% year on y...
CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme
CSPC Pharmaceutical Group Limited has announced a change in the trustee for its 2018 Share Award Scheme, a restricted share-based incentive plan for selected participants. With effect from 12 August 2026, BOCI Trustee (Hong Kong) Limited will replace...
CSPC Receives US$30 Million Upfront Payment from AstraZeneca for siRNA Collaboration
CSPC Pharmaceutical Group has received an upfront payment of US$30 million from AstraZeneca under their recently signed collaboration, option and license agreement. The funding follows the July 2026 deal to jointly develop novel small nucleic acid dr...
CSPC Launches First-in-Class CAR-T Trial for Refractory Lupus in China
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYS6063, a chimeric antigen receptor T-cell therapy designed to treat relapsed, refractory systemic lupus erythematosus. SYS6063 is described as the first CAR-T product usi...
CSPC Pharmaceutical Sets Board Meeting to Approve Interim Results
CSPC Pharmaceutical Group Limited has scheduled a board meeting for 20 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The announcement signals an upcoming disclosure of the company’s midye...
CSPC Wins U.S. FDA Nod for Clinical Trials of Novel Mpox mRNA Vaccine
CSPC Pharmaceutical Group has secured approval from the U.S. Food and Drug Administration to begin clinical trials of SYS6037, an mRNA-based mpox vaccine co-developed with the Institute of Microbiology of the Chinese Academy of Sciences. The vaccine...
CSPC Pharmaceutical Group Secures US$10 Million Milestone From AstraZeneca
CSPC Pharmaceutical Group has received a US$10 million milestone payment from AstraZeneca under their strategic research collaboration, following AstraZeneca’s exercise of a license option for one of CSPC’s pre-clinical candidate programs...
CSPC and AstraZeneca Form Biologics Manufacturing Joint Venture in China
CSPC Pharmaceutical Group has signed a joint venture contract with AstraZeneca to build a new-generation biologics manufacturing facility in Shijiazhuang, China. CSPC will hold 51 percent and AstraZeneca 49 percent of the venture, which initially wil...
CSPC Drug Combo for HER2-Positive Breast Cancer Wins Priority NMPA Review
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under priority review, a new drug application for Anbenitamab (KN026) combined with its self-developed albumin-bound docetaxel (HB1801) for...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Therapy for Colorectal Cancer in China
CSPC Pharmaceutical Group has initiated a Phase Ib/II clinical trial in China for SYS 6090 Injection, a Class 1 therapeutic biological product designed as a recombinant fully human PD-1 and IL-15 fusion protein for colorectal cancer. The therapy aims...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026